Static Chart InnoCare Pharma Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 09:08:07 05/07/2024 BST			5-day change	1st Jan Change
4.94 ^HKD	+1.86%		+2.49%	-28.30%

06-21	China Grants Priority Review Status for InnoCare's Lymphoma Drug; Shares Jump 6%	MT
06-20	InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	CI

Duration

Period